Researchers are developing dynamic magnetic field shielding techniques that could significantly lower the cost of magnetoencephalography, or MEG, potentially broadening access to brain imaging. The advances were highlighted at Q-BIOMED Connect 2026, a meeting at the Roy Dolby Centre, part of the Cavendish Laboratory, bringing together the quantum and healthcare fields.
Q-BIOMED Connect 2026: Bridging Quantum Research and Healthcare
Attendees at Q-BIOMED Connect 2026 identified a clear need to center clinical requirements when translating quantum sensing technologies into practical healthcare applications. A central panel discussion focused on the challenges and opportunities inherent in integrating these novel technologies into existing healthcare systems. The event highlighted a growing consensus regarding the essential partnerships and priorities needed to successfully move quantum sensing research to tangible improvements in patient care.
Participants emphasized that understanding genuine clinical need must be the starting point for any translational effort, a message consistently reinforced throughout the day’s conversations. This focus on practical application was further explored in an internal workshop where Q-BIOMED members identified new collaborative opportunities and addressed shared challenges.
The gathering revealed a shared sense of momentum within the quantum healthcare community, despite acknowledging the significant hurdles remaining before widespread clinical adoption, the company says. “We were delighted to bring together so many researchers, clinicians, industry partners, policymakers and funders, and to see new connections and potential collaborations emerge throughout the day,” stated an event spokesperson.
Organizers are already planning Q-BIOMED Connect 2027, anticipating continued dialogue and progress in this rapidly evolving field. The Quantum Standards Network, managed by the National Physical Laboratory and funded by the UK Government, also engaged with attendees to discuss standardization efforts.
Magnetoencephalography Advances and In Vitro Diagnostic Progress
Dr. Jon Breeze presented these findings at Q-BIOMED Connect 2026, detailing how these techniques aim to lessen the need for expensive, dedicated magnetically shielded rooms, a current limitation for widespread MEG implementation. This approach could significantly lower the barriers to entry for clinical and research facilities seeking to use this powerful neuroimaging modality. Quantum-enabled in vitro diagnostics are now undergoing testing with complex biological samples, moving beyond laboratory simulations toward practical application.
Researchers are evaluating these diagnostic tools using real blood and urine samples, with a specific focus on creating portable reader systems suitable for point-of-care settings. Professor Mete Atatüre, one of our Co-Directors, gave a welcome address followed by research updates from Q-BIOMED’s four flagship programmes. Together, the presentations demonstrated the breadth of activity taking place across the Hub, from new approaches to medical imaging and diagnostics through to quantum-enabled tools for cancer treatment and basic biomedical research.
Dominic Jones, Q-BIOMED’s Clinical Translation Lead, introduced the Clinical Needs Mapping project, an initiative designed to identify the highest priority clinical applications of quantum sensing technologies and explore the ways in which Q-BIOMED can best support developers of quantum sensing technologies to address them, according to the company. The Hub is also currently accepting applications for its funding programmes, with a deadline of November 15, 2026, offering early career researchers opportunities to gain interdisciplinary experience.
Quantum Sensors for Cancer Treatment and Biomedical Research
Professor Quentin Pankhurst demonstrated the potential of remotely detecting the magnetisation of nanoparticles used in magnetic thermotherapy, a technique that offers a highly sensitive method for targeting and treating cancerous tissues. Simultaneously, Professor Cristian Bonato highlighted collaborative efforts to create a complete pipeline for spin-active nanocrystals, encompassing material growth, characterisation, and sensing within living cells, furthering the exploration of new sensing materials for biomedical research. Dr Helena Knowles also provided an update on the Q-BIOMED Future Leaders Programme, detailing opportunities for early career researchers through Residencies, Secondments and Mobility Fellowship schemes.
Clinical Needs Mapping Drives Quantum Technology Translation
Identifying the most pressing clinical applications of quantum sensing is now a central focus for the Q-BIOMED Hub, with its Clinical Needs Mapping project designed to bridge the gap between technological advancement and patient benefit. The discussion drew expertise from clinical practice, policy, funding bodies, standards organizations and innovation specialists, consistently emphasizing that effective translation begins with a thorough understanding of genuine clinical need. Establishing clear standards is essential for facilitating this translation, ensuring all stakeholders operate with shared definitions and approaches, according to Dr Gemma Chapman, Business Development Manager at the Quantum Standards Network.
She highlighted that standards development is a long-term undertaking, advocating that researchers consider standards requirements early in the technology development process, and emphasizing the importance of community involvement in shaping frameworks to accurately reflect the needs and characteristics of emerging technologies on both national and international scales. The Q-BIOMED Connect 2026 meeting concluded with a networking reception sponsored by the Quantum Standards Network, providing a forum for attendees to explore potential collaborations and discuss future opportunities across the quantum technology sector, further solidifying connections vital for long-term impact., the firm reports.
See today’s quantum computing news on Quantum Zeitgeist for the latest breakthroughs in qubits, hardware, algorithms, and industry deals.
